ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAE
1
Company ACompany BContract Number, if applicableDate (M/D/Y)Date when KEI obtained the contractAmountAmount Details (brief)
Technology
URLType of AgreementPurposePaymentsLicensingIPNotes
2
PfizerBioNTech3/17/20202/2/2021$85,000,000
Upfront payment and equity investment to BioNTech; Regulatory milestone payment amount redacted
vaccinehttps://www.keionline.org/misc-docs/Pfizer-BioNTech-Collaboration-Agreement-17March2020.pdfCollaboration AgreementR&DPg 19Pg 27Pg 48Development costs shared 50%-50%
3
NovavaxSerum Institute7/30/20202/2/202150% of revenue from product salevaccine
https://www.keionline.org/misc-docs/SerumInstitute-Novavax-Supply-License-Agreement-30July2020.pdf
Supply and License Agreement
Commercialization & Manufacturing
Pg 14Pg 13Pg 16
Novavax retains 'step-in' rights (Pg 9); Territory definitions (pg. 37, 39, 40)
4
ModernaLonza2/2/2021
5
GlaxoSmithKlineVir Biotechnologies2/2/2021
6
AbCelleraEli Lilly2/2/2021
7
2/2/2021
8
2/2/2021
9
2/2/2021
10
2/2/2021
11
2/2/2021
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100